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Abstract 
Nurses and physicians working in forensic psychiatric facilities are 
frequently exposed to violent incidents at the hands of forensic psychiatric 
patients and inmates. Aside from seclusion, segregation and restraint, 
prevention serves as an efficient strategy in dealing with violence and 
aggression, including a proper medication regimen. This paper aims to address 
a specific clinical research question in terms of prevention of violence and 
aggression among forensic psychiatric patients, from a pharmaceutical 
perspective. Clinical Question: In forensic psychiatric patients with a history 
of aggression, is regular use of Clozapine more effective in reducing the 
incidence of violence and/or aggression than regular use of Haloperidol? Five 
primary research studies were found to be specific to the clinical question and 
its context. Review results: Resulting from its superior efficacy in treating 
complicated, positive schizophrenia symptoms, including violence and 
aggression, Clozapine may be better situated to prevent aggressive incidents 
among Forensic Patients with a history of aggression. Answering the clinical 
question has led to reflection and application of new recommendations of 
pharmaceutical interventions in a forensic setting.  
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Introduction 
Forensic psychiatric patients have a long history of violence and 
aggression towards staff, themselves and other residents. Nurses and 
physicians working in forensic psychiatric facilities are therefore frequently 
exposed to violent incidents at the hands of residents. There are many 
instigators to violence in this population, such as acute psychosis, 
disinhibition, personality disorders and being in an environment where 
violence and aggression is considered a cultural “norm” (Kelly et al., 2015). 
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Many strategies and safety measures have been employed in attempts 
to mitigate violence and aggression in the forensic setting. Likely due to the 
proliferation of new research, a paradigm shift in forensic psychiatry is 
emerging in which the use of locked seclusion, segregation and mechanical 
restraints are being discouraged while alternative solutions to aggression 
mitigation are being advocated. Presently, the most effective measure against 
the use of seclusion, segregation and restraint is that of prevention. Prevention 
has come in the form of risk assessments, a proper medication regimen and 
counseling (Fluttert et al, 2008). These strategies are conducive to healing and 
maintain therapeutic rapport with patients, through risk assessments, 1 on 1 
patient counseling and the use of PRN (pro re nata or as needed) medications 
in addition to regular medication regimens, in order to deal with feelings of 
anxiety, frustration and impulsivity (Fluttert et al., 2008; Kelly et al., 2015). 
However, other strategies still commonly employed to handle aggressive 
behaviour are more harmful, such as the use of locked seclusion and 
segregation, the use of mechanical restrains and the use of chemical restraints 
(Stoner et al., 2002).  
Despite this growing body of research about violence prevention, there 
is still much to learn about effective prevention strategies against violence and 
aggression, especially in forensic psychiatric patients. 
While this paper briefly outlines some of the emerging data, research 
and strategies being employed in the prevention of violence and aggression 
among forensic psychiatric patients, a full analysis and review of these 
strategies is beyond its scope. Instead, this paper aims to address a specific 
clinical research question about the prevention of violence and aggression 
through the administration of psychotropic drugs, among forensic psychiatric 
patients. In forensic psychiatric patients with a history of aggression, is regular 
use of Clozapine more effective in reducing the incidence of violence and/or 
aggression than regular use of Haloperidol? 
 
Clinical Question  
The population of forensic psychiatric patients may be considered a 
relatively broad term, as it represents a specific demographic segment, with 
multifactorial characteristics that predispose them to violence and aggression. 
These may include diagnoses of major psychiatric illness such as 
schizophrenia, or otherwise personality disorders such as antisocial 
personality, a history of violent behaviour and living in an environment in 
which violence and aggression are cultural “norms”.  
The clinical question refers to an intervention in administering 
Haloperidol (Haldol) or Clozapine (Clozaril) targeting the specific outcome of 
reducing / eliminating aggression and violence. The comparison will uncover 
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witch of the two medications produces a more significant effect in the 
prevention of aggression and violence. 
These specific interventions become the focus of the clinical question 
as it relates to the extensive use of the two medications in forensic psychiatry. 
Violence/aggression is viewed here in terms of violent acts, aggressive 
outbursts (yelling, shouting, and threatening) and includes staff injuries 
associated with patient behaviour. 
 
Clinical Reasoning  
 Any clinical question being proposed needs to have a sound, clinical 
rationale. While many therapies and interventions in medicine and nursing 
have been found to be effective without a well understood causality, it is still 
important, when posing any clinical question, to ensure that the question is 
processed based on clinical evidence and knowledge. In fact, Hoffmann, 
Bennett and Del Mar (2013) argue that knowledge is a fundamental 
requirement for the effective implementation of evidence-based practice.  
 Haloperidol and Clozapine are both atypical antipsychotics, 
predominantly used in treating schizophrenia (Citrome & Volavka, 2013). 
Clozapine has generally been reserved for severe and refractory cases of 
schizophrenia, especially in patients who exhibit aggression (Chengappa et al., 
2002). Studies comparing Clozapine to Haloperidol have found that patients 
receiving Clozapine experience generally less side effects, including less 
incidences of tardive dyskinesia and extrapyramidal side effects, which might 
explain why patients receiving Clozapine show better adherence to therapy 
(Kane et al., 2001; Kurz et al., 1995), less hospital stays, and less withdrawal 
symptoms. However, Clozapine has been found to elicit more severe and life-
threatening side effects when they do occur (Stoner et al., 2002).   
Both Haloperidol and Clozapine have been indicated in the treatment 
of aggression. Clozapine use, however, proves more delicate and complex. It 
was originally developed in the 1960s but removed from the Canadian market 
as a result of its serious side effects in 1975.  It was released again in Canada 
in 1991 (Government of Canada, 2018).  While Clozapine elicits less 
extrapyramidal side effects compared to Haloperidol, Clozapine also has an 
FDA issued black box warning due to possibly serious side effects, including 
agranulocytosis, a potentially life-threatening complication (Citrome & 
Volavka, 2013).    
The seriousness of the side effects has elicited the requirement of 
frequent monitoring of blood work and vigilant assessment of residents taking 
Clozapine, particularly when associated to any febrile illness. In fact, patients 
on Clozapine must have their blood work sent to the manufacturer, Novartis, 
for continued assessment. Failure of a patient or physician to submit blood 
work could induce refusal of the manufacturer to provide the patient with 
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Clozapine. Since 2003 there have been generic alternatives to Clozapine, 
which has added complexity to the monitoring process, otherwise simplified 
in the context of a single manufacturer (Government of Canada, 2018).  The 
severity of side effects of Clozaril and the complex monitoring requirements 
has caused a great deal of anxiety among practitioners and has lead Clozapine 
to be a “last resort therapy” despite the promising research findings. However, 
Clozapine has not been found to be of any clinical utility in treating negative 
symptoms of schizophrenia (Rosenheck et al, 1999).  Notably, negative 
symptoms of schizophrenia are not usually associated with aggression and 
violence (Ko et al., 2007).  
Resulting from its superior efficacy in treating complicated, positive 
schizophrenia symptoms, including violence and aggression, Clozapine may 
be better situated to prevent aggressive incidents among Forensic Patients with 
a hist ory of aggression.  
 
Method and design  
 While the clinical question is specific in nature, in order to gain a full 
and complete understanding of the evidence, it is important to review multiple 
different sources of reference. It is also important to understand that not all 
research is of equal methodological rigour and therefore all available evidence 
specific to the topic should be selected, reviewed and analyzed for significance 
(Hoffmann et al, 2013).  
 The best research paradigm to answer the clinical question would be 
that of a systematic review of the literature and a quantitative analysis of the 
evidence. Particular attention is being given to studies based on a randomized 
controlled trial (RCT) method, considered most appropriate in answering the 
research question. Alternative research methods may be of use, such as 
observational studies including cohort and case control studies. In fact, 
research has shown that observational studies can provide as much accuracy 
as RCTs in delineating effectiveness of interventions. However, while in the 
process of making clinical decisions, Hoffmann et al. (2013) suggest following 
the clinical evidence hierarchy in which RCTs are the gold standard for 
consideration in practice decisions.  
 In searching to answer the posed clinical question, a group of key terms 
were used and combined with Boolean operators to ensure that research 
articles were specific enough to the question and to aid in the elimination of 
irrelevant research. Truncation was also used where appropriate. The key 
concepts of the research question are Clozapine and Haldol, violence and/or 
aggression. Forensic psychiatry, while indeed framing the context and being 
significant to the question being proposed, does not exclude similar research 
done outside of a forensic setting. As a result, the key term forensic was 
included in the key terms; however, it was also left out of some searches as to 
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ensure that all research investigating violence and aggression and its 
relationship to Clozapine and Haloperidol use were reviewed. No year limit 
was placed on the search criteria, permitting the retrieval of any research that 
may exist on this topic.  
The databases used in the search included: Medline, PubMed, 
ProQuest Nursing and Allied Health and PsychINFO. The following are the 
key terms used along with the hits they produced: 
Clozapine AND Haloperidol AND aggression OR violence AND forensic 
patients = 141 
Clozapine AND aggression AND violence = 20  
Clozapine AND haloperidol AND aggression = 19  
Clozapine AND haloperidol AND aggression AND forensic = 2  
In searching for evidence, emphasis was placed on studies using RCT 
and/or observational methods. The abstracts of articles matching the key terms 
of Clozapine or Clozaril and Haloperidol or Haldol were briefly reviewed. If 
the abstract indicated that the study was in fact a primary study, investigating 
in some capacity, the effects of Haloperidol and Clozapine and its relation to 
violence and/or aggression, the study was reviewed for consideration in 
answering the clinical question. The language was restricted to English for 
simplicity.  
A set of inclusion and exclusion criteria were used to determine which 
studies to review and select. The following were the inclusion criteria, or the 
criteria that was necessary for the article to be selected: being a primary 
research study; investigate, in some capacity, violence and/or aggression in 
forensic psychiatric or general psychiatric patients with a history of 
aggression; Clozapine usage and Haloperidol usage. The only exclusion 
criteria applied was that of research investigating aggression in pediatric 
psychiatry, as forensic treatment units generally treat adult patients. 
In total, 5 primary research studies were found to be specific to the 
clinical question and its context. One of the studies used a randomized, double 
blinded design over 6 months (Volavka et al., 2004), one study was a 
prospective naturalistic study (Bitter et al., 2005), one was a naturalistic, 
retrospective database analysis (Stoner et al., 2002), one was a non-
randomized six-month study (Spivaket et al., 2003) and another one was a 
mirror image study, an observational type design (Chengappa et al., 2002). 
Dates of publications range between 2002-2005. Sample size ranged from 44 
to 7,655 for a total of N=8,077 for all studies.  
There were multiple other studies investigating different antipsychotic 
medications, such as Quetapine and Risperidone, in its mitigation of violence 
and/or aggression. While some of these studies were briefly reviewed, they 
did not serve to answer the specific question at hand, which is that of the 
effectiveness of haloperidol vs. clozapine in the prevention of 
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aggression/violence and thus were considered not relevant in answering the 
specific clinical question. 
 
Summary of Results  
The selected research studies are quite diverse and vary in their 
primary aim of study. All of them investigated aggression and violence in 
some capacity and the effect that Haloperidol and/or Clozapine had on 
violence. One study by Chengappa et al. (2002) investigated Clozapine vs. all 
other antipsychotic medications that patients were prescribed in a state 
psychiatric hospital. However, these authors indicated that the non-Clozapine 
treated group was primarily treated with “first generation neuroleptic agents” 
(p.4) which would include Haloperidol. These authors also stated that “At the 
time of the study, other second generation antipsychotic agents such as 
risperidone, olanzapine or quetiapine were not available” (p.4).  
All but one of the authors (Bitter et al., 2005) found that Clozapine 
treated patients displayed a significant reduction in violent 
behavior/aggression, compared to Haloperidol treated patients. However, in 
their prospective, naturalistic study, Bitter et al. (2005) found that Olanzapine 
and Risperidone were significantly superior to Haloperidol and Clozapine in 
reducing violence. Interestingly, in the study by Volavka et al. (2004), it was 
reported that Risperidone and Olanzapine showed better improvement in 
psychotic symptoms in patients who exhibited less aggressive behaviours. 
However, in patients with more aggressive behaviour, Clozapine was superior 
to all antipsychotics including Haloperidol.  
The most common diagnosis of participants in the five studies was 
schizophrenia. Stoner et al. (2002) investigated the effectiveness of 
Haloperidol and Clozapine in reducing aggressive incidence among forensic 
patients who had committed violent crimes (including assault, armed criminal 
actions and burglary) and found that patients using haloperidol were more 
likely to have their conditional release revoked, in part, due to aggressive and 
violent behaviour, whereas those treated with Clozapine were less likely to 
have their conditional release revoked and showed better participation in 
outpatient programs.   Only two studies were forensic specific (Chengappa et 
al., 2002; Stoner et al., 2002), the rest included outpatients with schizophrenia 
and a history of violence. 
 
Merit of Evidence and Implications for Practice 
 Of the 182 studies found to contain the above mentioned key terms, 5 
met the inclusion criteria. While the retained research may guide clinical 
decision making, it also highlights the need for more, high quality research on 
the true effects of different antipsychotics and their prevention of aggression 
in forensic psychiatry.  
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 As indicated previously, only two studies were specific to forensic 
psychiatry (Chengappa et al., 2002; Stoner et al., 2002). The remainder looked 
at outpatients with a history of violent behaviour. While plenty of research 
exists on the incidence, prevalence and causes of violence in forensic 
psychiatry, more is currently needed to review the potential implications of 
pharmacotherapy as prevention for aggression and violence within a forensic 
psychiatric context.  
 However, specifically to the research question, the evidence does show 
that Clozapine appears to have a better effect than Haloperidol in the 
prevention of violence and aggression among psychiatric populations with a 
history of aggression. Receiving Clozapine also appears to reduce violent 
behavior in forensic psychiatric settings, therefore reducing the need to use 
both seclusion and restraint (Chengappa et al., 2002). The challenge of 
Clozapine administration remains the monitoring of side effects and the 
requirement of adequate, therapeutic dosing before the real effects of 
Clozapine are seen (Volavka et al., 2004).  
 
Conclusion 
 While the retained and reviewed research does answer the clinical 
question, the process of reviewing the literature lead to the development of 
further clinical questions and highlighted the need for further, forensic specific 
research. Perhaps, comparisons including other psychotropic formulas could 
lead to novel strategies of administration of antipsychotics, or a combination 
of therapeutic methods may prove more efficient in controlling violent 
outbursts. For this paper, a total of five primary research studies of 182 articles 
were selected for review. Key terms, as well as inclusion and exclusion criteria 
were developed and followed in order to ensure the found research was 
specific and relevant to the topic under investigation. Answering the clinical 
question has also led to reflection and application of new recommendations of 
pharmaceutical interventions in a forensic setting.  
 
References: 
1. Bitter, I., Czobor, P., Dossenbach, M. & Volavka, J. (2005) 
Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and 
haloperidol monotherapy in reducing hostile and aggressive behavior 
in outpatients treated for schizophrenia : a prospective naturalistic 
study. European Psychiatry, 20(5-6), 403-408. 
2. Chengappa, R., Goldstein, J., Greenwood, M., John, V. & Levine, J. 
(2003) A post hoc  analysis of the impact on hostility and agitation 
of quetiapine and haloperidol among  patients with schizophrenia 
(English). Clinical Therapeutics, 25(2), 530-541. 
European Scientific Journal August 2019 edition Vol.15, No.24 ISSN: 1857 – 7881 (Print) e - ISSN 1857- 7431 
415 
3. Chengappa, R., Vasile, J., Levine, J., Ulrich, R., Baker, R., Gopalani, 
A., & Schooler, N. (2002).  Clozapine: its impact on aggressive 
behavior among patients in a state psychiatric  hospital 
(English). Schizophrenia Research, 53(1-2), 1-6. 
4. Citrome, L. & Volavka, J. (2013).  Pharmacological Management of 
Acute and Persistent  Aggression in Forensic Psychiatry Settings 
(English). CNS Drugs, 25(12), 1009-1021. 
5. Fluttert, F., Van Meijel, B., Webster, C., Nijman, H., Bartels, A., & 
Grypdonck, M. (2008). Risk  management by early recognition of 
warning signs in patients in forensic psychiatric  care. Archives 
Of Psychiatric Nursing, 22(4), 208-216. 
6. Government of Canada (2018).  Summary Safety Review – Clozapine 
– Assessing the ffectiveness of monitoring for low numbers of white 
blood cells.  Retrieved online July 22, 2019 from  
https://www.canada.ca/en/health-canada/services/drugs-health-
products/medeffect-canada/safety-reviews/clozapine-white-blood-
cells.html 
7. Hoffmann, T., Bennett, S. & Del Mar, C. D. (2013). Evidence-Based 
Practice Across the Health  Professions. Elsevier, 432 pages.  
8. Kane, J., Marder, S., Schooler, N., Wirshing, W., Umbrictt, D., Baker, 
R., & ... Borenstein, M.,  (2001). Clozapine and haloperidol in 
moderately refractory schizophrenia: A 6-month  randomized and 
double-blind comparison (English). Archives Of General Psychiatry, 
58(10), 965-972. 
9. Kelly, E. L., Subica, A. M., Fulginiti, A., Brekke, J. S., & Novaco, R. 
W. (2015). A cross- sectional survey of factors related to inpatient 
assault of staff in a forensic psychiatric  hospital. Journal Of 
Advanced Nursing, 71(5), 1110-1122.  
10. Ko, Y., Jung, S., Joe, S., Lee, C., Jung, H., Jung, I., & Lee, M. (. (2007). 
Association between  serum testosterone levels and the severity of 
negative symptoms in male patients with  chronic schizophrenia 
(English). Psychoneuroendocrinology, 32(4), 385-391. 
11. Kurz, M., Hummer, M., Oberbauer, H. & Fleischhacker, W. (1995).  
Extrapyrimidal side effects of clozapine and haloperidol.  
Psychophamacology, 118(1), 52-56. 
12. Ontario Drug Benefit Formulary/Comparative Drug Index (2019).  
Retrieved online July 22nd 2019 from 
https://www.formulary.health.gov.on.ca/formulary/. 
13. Rosenheck, R., Cramer, J., Xu, W., Thomas, J., Henderson, W. & 
Frisman, L. (1997). A  comparison of clozapine and 
haloperidol in hospitalized patients with refractory  schizophrenia 
(English). The New England Journal Of Medicine, 337(12), 809-815. 
European Scientific Journal August 2019 edition Vol.15, No.24 ISSN: 1857 – 7881 (Print) e - ISSN 1857- 7431 
416 
14. Rosenheck, R., Dunn, L., Peszke, M., Cramer, J., Weichun, X., 
Thomas, J., & Charney, D.  (1999). Impact of clozapine on negative 
symptoms and on the deficit syndrome in  refractory schizophrenia 
(English). The American Journal Of Psychiatry, 156(1), 88-93. 
15. Spivak, B., Shanash, E., Sheitman, B., Weizman, A., & Mester, 
R.(2003). The effects of  clozapine versus haloperidol on 
measures of impulsive aggression and suicidality in  chronic 
schizophrenia patients: An open, nonrandomized, 6-month study 
(English). The  Journal Of Clinical Psychiatry, 64(7), 755-76. 
16. Stoner, S., Lea, J., Dubisar, B., Roebuck-Colgan, K., & Vlach, D. 
(2002). Impact of clozapine  versus haloperidol on conditional 
release time and rates of revocation in a forensic  psychiatric 
population. Journal Of Pharmacy Technology, 18(4), 182-186. 
17. Volavka, J., Czobor, P., Nolan, K., Sheitman, B., Lindenmayer, J., 
Citrome, L., & Lieberman, J.  (2004). Overt aggression and psychotic 
symptoms in patients with schizophrenia treated  with clozapine, 
olanzapine, risperidone, or haloperidol. Journal Of Clinical 
Psychopharmacology, 24(2), 225-228. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
